DR was found in 140 patients (70.35%), which included 34 patients (17.1%) with mild non proliferative DR (NPDR), 34 patients (17.1%) with moderate NPDR, 22 patients (11.1%) with severe NPDR and 25 ...
Our HELIOS study has demonstrated that a single injection of AXPAXLI has the potential to reduce the risk of vision loss in NPDR to literally zero at 48 weeks. In HELIOS, every single patient with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback